Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04187872 · ClinicalTrials.gov registry record · Phase 1

LITT and Pembrolizumab in Recurrent Brain Metastasis

A Phase 1 study, sponsored by University of Florida.

Terminated
Registry status
Phase 1
Development phase
10
Enrollment target

NCT04187872: Clinical Trial Phase 1 study, sponsored by University of Florida.

NCT04187872 is a Phase 1 study that was terminated before completion, run by University of Florida. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04187872, a Phase 1 study, was terminated before completion, sponsored by University of Florida.

TERMINATED
Registry status
Phase 1
Development phase
10 participants
Enrollment target

Study Summary

This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).

Primary Outcome

Immune profile of peripheral blood mononuclear cells (PBMCs) as measured by RNA sequencing; analysis will be performed through serial blood draws and will compare each analysis to the patient's baseline prior to treatment.

Interventions

  • COMBINATION_PRODUCT LITT + Pembrolizumab

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-01-10
Est. Completion 2023-12-01
Phase Phase 1
University of Florida

1,106 total trials

Why NCT04187872 stopped before completion

NCT04187872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 1 intervention - of which LITT + Pembrolizumab is the first listed.

NCT04187872 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04187872 about?

NCT04187872 is a clinical study titled "LITT and Pembrolizumab in Recurrent Brain Metastasis". This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after...

What is the current status of trial NCT04187872?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-01-10. Estimated completion is 2023-12-01.

What interventions are being tested in trial NCT04187872?

The interventions under investigation include: LITT + Pembrolizumab (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT04187872?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04187872's enrollment target sits among peer trials

10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04187872, the US trial registry maintained by the National Library of Medicine. NCT04187872 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.